Skip to main content


Page 37 of 38

  1. The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases.

    Authors: Norma Malavasi, Giovanni Ponti, Roberta Depenni, Federica Bertolini, Sandra Zironi, Gabriele Luppi and Pier Franco Conte
    Citation: Journal of Hematology & Oncology 2009 2:35
  2. Ex vivo activation and expansion of lymphocytes for adoptive cell therapy has demonstrated great success. To improve safety and therapeutic efficacy, increased antigen specificity and reduced non-specific respons...

    Authors: Shuhong Han, Yuju Huang, Yin Liang, Yuchin Ho, Yichen Wang and Lung-Ji Chang
    Citation: Journal of Hematology & Oncology 2009 2:34
  3. The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine...

    Authors: Jianmin Wang, Shuqing Lü, Jianmin Yang, Xianmin Song, Li Chen, Chongmei Huang, Jun Hou and Weiping Zhang
    Citation: Journal of Hematology & Oncology 2009 2:32
  4. Vorinostat (Zolinza®), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma...

    Authors: David Siegel, Mohamad Hussein, Chandra Belani, Francisco Robert, Evanthia Galanis, Victoria M Richon, José Garcia-Vargas, Cesar Sanz-Rodriguez and Syed Rizvi
    Citation: Journal of Hematology & Oncology 2009 2:31
  5. In the last decade the importance of ethnicity, socio-economic and gender differences in relation to disease incidence, diagnosis, and prognosis has been realized. Differences in these areas have become a majo...

    Authors: Justin P Lee, Elliott Birnstein, David Masiello, Dongyun Yang and Allen S Yang
    Citation: Journal of Hematology & Oncology 2009 2:30
  6. Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete response (CR) rates and progression free survival (PFS). Despite these advances, CLL ...

    Authors: Kami J Maddocks and Thomas S Lin
    Citation: Journal of Hematology & Oncology 2009 2:29
  7. RIZ1 expression and activity are reduced in many cancers. In AML cell lines and patient material, RIZ1 expression is reduced relative to normal bone marrow. In chronic myelogenous leukemia (CML), blastic trans...

    Authors: Ashakumary Lakshmikuttyamma, Naoto Takahashi, Elodie Pastural, Emina Torlakovic, Hesham M Amin, Guillermo Garcia-Manero, Michael Voralia, Magdalena Czader, John F DeCoteau and C Ronald Geyer
    Citation: Journal of Hematology & Oncology 2009 2:28
  8. Rheumatoid arthritis (RA) is an autoimmune disease mediated by inflammatory processes mainly at the joints. Recently, awareness of Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD...

    Authors: Michihide Tokuhira, Kyoko Hanzawa, Reiko Watanabe, Yasunobu Sekiguchi, Tomoe Nemoto, Yasuo Toyozumi, Jun-ichi Tamaru, Shinji Itoyama, Katsuya Suzuki, Hideto Kameda, Shigehisa Mori and Masahiro Kizaki
    Citation: Journal of Hematology & Oncology 2009 2:27
  9. Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of lymphoblasts in the periph...

    Authors: Farhat Abbas Bhatti, Iftikhar Hussain and Muhammad Zafar Ali
    Citation: Journal of Hematology & Oncology 2009 2:26
  10. Non-prescriptional use of medicinal herbs among cancer patients is common around the world. The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in vitro or in vivo ani...

    Authors: Godfrey Chi-Fung Chan, Wing Keung Chan and Daniel Man-Yuen Sze
    Citation: Journal of Hematology & Oncology 2009 2:25
  11. The ability to screen blood of early stage operable breast cancer patients for circulating tumour cells is of potential importance for identifying patients at risk of developing distant relapse. We present the...

    Authors: Michael P Raynor, Sally-Anne Stephenson, Kenneth B Pittman, David CA Walsh, Michael A Henderson and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2009 2:24
  12. Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, ...

    Authors: Tara K Gregory, David Wald, Yichu Chen, Johanna M Vermaat, Yin Xiong and William Tse
    Citation: Journal of Hematology & Oncology 2009 2:23
  13. Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fift...

    Authors: Karen Seiter, Sreedhar Katragadda, Doris Ponce, Muhammad Rasul and Nasir Ahmed
    Citation: Journal of Hematology & Oncology 2009 2:21
  14. Ezatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1 inhibitor, was evaluated in myelodysplastic syndrome (MDS). The objectives were to determine the safety, pharmacokinetics, and...

    Authors: Azra Raza, Naomi Galili, Natalie Callander, Leonel Ochoa, Lawrence Piro, Peter Emanuel, Stephanie Williams, Howard Burris III, Stefan Faderl, Zeev Estrov, Peter Curtin, Richard A Larson, James G Keck, Marsha Jones, Lisa Meng and Gail L Brown
    Citation: Journal of Hematology & Oncology 2009 2:20
  15. Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in as...

    Authors: Zhen-gang Yuan, Xiao-yi Dun, Yong-hua Li and Jian Hou
    Citation: Journal of Hematology & Oncology 2009 2:19
  16. Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epi...

    Authors: David Z Chang, Vikas Kumar, Ying Ma, Kuiyuan Li and Scott Kopetz
    Citation: Journal of Hematology & Oncology 2009 2:18
  17. We studied serum proteomic profiling in patients with graft versus host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) by two-dimensional gel electrophoresis (2-DE) and mass spec...

    Authors: Joseph McGuirk, Gang Hao, Weijian Hou, Sunil Abhyankar, Casey Williams, Weisi Yan, Jianda Yuan, Xiuqin Guan, Robert Belt, Shaun Dejarnette, Jeffery Wieman and Ying Yan
    Citation: Journal of Hematology & Oncology 2009 2:17
  18. Malignant tumors that involve the skull base pose significant challenges to the clinician because of the proximity of critical neurovascular structures and limited effectiveness of surgical resection without m...

    Authors: Nicholas D Coppa, Daniel MS Raper, Ying Zhang, Brian T Collins, K William Harter, Gregory J Gagnon, Sean P Collins and Walter C Jean
    Citation: Journal of Hematology & Oncology 2009 2:16
  19. Human β-globin disorders are relatively common genetic diseases cause by mutations in the β-globin gene. Increasing the expression of the γ-globin gene has great benefits in reducing complications associated with...

    Authors: Xiaoxin S Xu, Xin Hong and Gan Wang
    Citation: Journal of Hematology & Oncology 2009 2:15
  20. R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) have both been used successfully in the treatment of pa...

    Authors: Ganguly Siddhartha and Patel Vijay
    Citation: Journal of Hematology & Oncology 2009 2:14
  21. Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and ev...

    Authors: Bernardo HL Goulart, Jeffrey W Clark, Gregory Y Lauwers, David P Ryan, Nina Grenon, Alona Muzikansky and Andrew X Zhu
    Citation: Journal of Hematology & Oncology 2009 2:13
  22. Cholestatic jaundice as a presenting symptom of Precursor T-lymphoblastic leukemia (T-ALL)/lymphoma (T-LBL) has never been reported in literature. Similarly, precursor T-ALL/T-LBL is characteristically negativ...

    Authors: Kevin J Patel, Sahibzada U Latif and Wanderley M de Calaca
    Citation: Journal of Hematology & Oncology 2009 2:12
  23. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL). The latest...

    Authors: Brady Beltran, Jorge Castillo, Renzo Salas, Pilar Quiñones, Domingo Morales, Fernando Hurtado, Luis Riva and Eric Winer
    Citation: Journal of Hematology & Oncology 2009 2:11
  24. We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have disc...

    Authors: Milind Javle and Chung-Tsen Hsueh
    Citation: Journal of Hematology & Oncology 2009 2:9
  25. The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy ...

    Authors: Ayad M Al-Katib, Yuan Sun, Anton Scott Goustin, Asfar Sohail Azmi, Ben Chen, Amro Aboukameel and Ramzi M Mohammad
    Citation: Journal of Hematology & Oncology 2009 2:8
  26. Recent research has supported that a variety of cytokines play important roles during radiation-induced lung toxicity. The present study is designed to investigate the differences in early cytokine induction a...

    Authors: Xiaoping Ao, Lujun Zhao, Mary A Davis, David M Lubman, Theodore S Lawrence and Feng-Ming Kong
    Citation: Journal of Hematology & Oncology 2009 2:6
  27. We highlight the orbital manifestations of acute myeloid leukemia and the role of peripheral blood smear in the diagnosis of these cases. A total of 12 patients who presented with proptosis and were subsequent...

    Authors: Ramesh Murthy, Geeta K Vemuganti, Santosh G Honavar, Milind Naik and Vijayanand Reddy
    Citation: Journal of Hematology & Oncology 2009 2:4
  28. SET-NUP214 fusion resulting from a recurrent cryptic deletion, del(9)(q34.11q34.13) has recently been described in T-cell acute lymphoblastic leukemia (T-ALL) and in one case of acute myeloid leukemia (AML). The ...

    Authors: Hilmar Quentmeier, Björn Schneider, Sonja Röhrs, Julia Romani, Margarete Zaborski, Roderick AF MacLeod and Hans G Drexler
    Citation: Journal of Hematology & Oncology 2009 2:3
  29. Curative surgery is not an option for many patients with clinical stage I non-small-cell lung carcinoma (NSCLC), but radical radiosurgery may be effective.

    Authors: Brian T Collins, Saloomeh Vahdat, Kelly Erickson, Sean P Collins, Simeng Suy, Xia Yu, Ying Zhang, Deepa Subramaniam, Cristina A Reichner, Ismet Sarikaya, Giuseppe Esposito, Shadi Yousefi, Carlos Jamis-Dow, Filip Banovac and Eric D Anderson
    Citation: Journal of Hematology & Oncology 2009 2:1
  30. Concurrent hemolysis in patients with vitamin B12 deficiency is a well-recognized phenomenon and has been attributed to intramedullary destruction of erythrocytes (ineffective erythropoiesis). Recent studies r...

    Authors: Utkarsh Acharya, Jen-Tzer Gau, William Horvath, Paolo Ventura, Chung-Tsen Hsueh and Wayne Carlsen
    Citation: Journal of Hematology & Oncology 2008 1:26
  31. Prostate cancer remains the most common malignancy among elderly men and the second leading cause of cancer death in the United States. Although several conventional therapies are currently available, they hav...

    Authors: Paul Pyo, Brandon Louie, Srinivas Rajamahanty, Muhammad Choudhury and Sensuke Konno
    Citation: Journal of Hematology & Oncology 2008 1:25
  32. The etiology of venous thromboembolism in young patients is frequently associated with hereditary coagulation abnormalities, immunologic diseases, and neoplasia. The advent of radiological advances, namely Com...

    Authors: Cannon Milani, Maria Constantinou, David Berz, James N Butera and Gerald A Colvin
    Citation: Journal of Hematology & Oncology 2008 1:24
  33. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome (TTP-HUS) are related and uncommon disorders with a high fatality and complication rate if untreated. Plasma exchange therapy has been show...

    Authors: Mark Levandovsky, Danielle Harvey, Primo Lara and Ted Wun
    Citation: Journal of Hematology & Oncology 2008 1:23
  34. Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along wi...

    Authors: Yiu-Keung Lau, Manpreet K Chadha, Alan Litwin and Donald L Trump
    Citation: Journal of Hematology & Oncology 2008 1:21
  35. This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, G...

    Authors: Andrea Molckovsky and Lillian L Siu
    Citation: Journal of Hematology & Oncology 2008 1:20
  36. Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood (CB) expansion. In this study, we report the effects of anit-CD52 (Alemtuzumab, Campath)...

    Authors: Che K Lim, Li Sun, Qi Feng, Ping Law, Wei T Chua, Shy N Lim and William YK Hwang
    Citation: Journal of Hematology & Oncology 2008 1:19

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    9,883 Altmetric mentions 

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here